Scholars Central

Research articlePublished 27 Dec 2022

SUPERIORITY OF ENHERTU; A QUESTION TO BE ANSWERED

Authors: Athira Jayaraj

Journal of Research in Medical and Dental Science

Volume 10 · Issue 12 · Pages 28–30

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Approximately 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). Trastuzumab emtansine is the standard treatment for patients with HER2 –positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxane. The recent approval of trastuzumab deruxtecan (Enhertu) based on phase 3, multicenter, open-label, randomized trial which compared the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with trastuzumab emtansine. In the present mini-review, we discuss recent findings of clinical studies concerning the pros and cons of Enhertu.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Research in Medical and Dental Science.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Research in Medical and Dental Science
  • SubjectDentistry & Oral Health
  • BylineArticles whose byline prints “Athira Jayaraj”